A new effect of IL-4 on human γδ cells: Promoting regulatory Vδ1 T cells via IL-10 production and inhibiting function of Vδ2 T cells

Cellular and Molecular Immunology

Volumn 13, Issue 2, 2016, Pages 217-228

  Mao, Yujia ^a   Yin, Shanshan ^a   Zhang, Jianmin ^a,b   Hu, Yu ^a,b   Huang, Bo ^a   Cui, Lianxian ^a,b   Kang, Ning ^a,b   He, Wei ^a,b  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b State Key Laboratory of Molecular Oncology   (China)

Author keywords

cytokines; signal transduction; T cells; T cell receptors; tumor immunity

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; MARKER; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NATURAL KILLER CELL RECEPTOR NKG2D; PHOSPHOLIPASE C GAMMA1; SLP76 PROTEIN; STAT6 PROTEIN; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; IFNG PROTEIN, HUMAN; IL10 PROTEIN, HUMAN; IL4 PROTEIN, HUMAN; LYMPHOCYTE ANTIGEN RECEPTOR;

ADULT; ARTICLE; CALCIUM TRANSPORT; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; GAMMA DELTA T LYMPHOCYTE; GROWTH INHIBITION; HUMAN; HUMAN CELL; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; NORMAL HUMAN; PROTEIN PHOSPHORYLATION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VARIABLE DELTA 1 T CELL; VARIABLE DELTA 2 T CELL; IMMUNOLOGY; NEOPLASM; T LYMPHOCYTE;

HUMANS; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-4; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTES;

EID: 84959904517     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2015.07     Document Type: Article

References (57)

1. Kabelitz D, Wesch D, He W. Perspectives of gammadelta T cells in tumor immunology. Cancer Res 2007; 67: 5-8.
2. Thedrez A, Sabourin C, Gertner J, Devilder MC, Allain-Maillet S, Fournie JJ et al. Self/non-self discrimination by human gammadelta T cells: simple solutions for a complex issue? Immunol Rev 2007; 215: 123-135.
3. Hayday AC. [gamma][delta] cells: a right time and a right place for a conserved third way of protection. Annu Rev Immunol 2000; 18: 975-1026.
4. Willcox CR, Pitard V, Netzer S, Couzi L, Salim M, Silberzahn T et al. Cytomegalovirus and tumor stress surveillance by binding of a human gammadelta T cell antigen receptor to endothelial protein C receptor. Nat Immunol 2012; 13: 872-879.
5. Gober HJ, Kistowska M, Angman L, Jeno P, Mori L, de Libero G. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 2003; 197: 163-168.
6. Bonneville M, O'Brien RL, Born WK. Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity. Nat Rev Immunol 2010; 10: 467-478.
7. Champagne E. gammadelta T cell receptor ligands and modes of antigen recognition. Arch Immunol Ther Exp (Warsz) 2011; 59: 117-137.
8. Wu H, Knight JF, Alexander SI. Regulatory gamma delta T cells in Heymann nephritis express an invariant Vgamma6/Vdelta1 with a canonical CDR3 sequence. Eur J Immunol 2004; 34: 2322-2230.
9. Kuhl AA, Pawlowski NN, Grollich K, Blessenohl M, Westermann J, Zeitz M et al. Human peripheral gammadelta T cells possess regulatory potential. Immunology 2009; 128: 580-588.
10. + T cells expressing the natural cytotoxicity receptor NKp30 for recognition of lymphoid leukemia cells. Blood 2011; 118: 992-1001.
11. Groh V, Steinle A, Bauer S, Spies T. Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells. Science 1998; 279: 1737-1740.
12. Knight A, Mackinnon S, Lowdell MW. Human Vdelta1 gamma-delta T cells exert potent specific cytotoxicity against primary multiple myeloma cells. Cytotherapy 2012; 14: 1110-1118.
13. + lymphocytes recognize tumor cells of epithelial origin. J Exp Med 1996; 183: 1681-1696.
14. Poggi A, Venturino C, Catellani S, Clavio M, Miglino M, Gobbi M et al. Vdelta1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid. Cancer Res 2004; 64: 9172-9179.
15. Dechanet J, Merville P, Lim A, Retiere C, Pitard V, Lafarge X et al. Implication of gammadelta T cells in the human immune response to cytomegalovirus. J Clin Invest 1999; 103: 1437-1449.
16. Fenoglio D, Poggi A, Catellani S, Battaglia F, Ferrera A, Setti M et al. Vdelta1 T lymphocytes producing IFN-gamma and IL-17 are expanded in HIV-1-infected patients and respond to Candida albicans. Blood 2009; 113: 6611-6618.
17. - γδT cells against cytomegalovirus-infected cells and tumor intestinal epithelial cells. J Exp Med 2005; 201: 1567-1578.
18. Peng G, Wang HY, Peng W, Kiniwa Y, Seo KH, Wang RF. Tumorinfiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique Toll-like receptor signaling pathway. Immunity 2007; 27: 334-348.
19. Li Y, Koshiba T, Yoshizawa A, Yonekawa Y, Masuda K, Ito A et al. Analyses of peripheral blood mononuclear cells in operational tolerance after pediatric living donor liver transplantation. Am J Transplant 2004; 4: 2118-2125.
20. Martinez-Llordella M, Puig-Pey I, Orlando G, Ramoni M, Tisone G, Rimola A et al. Multiparameter immune profiling of operational tolerance in liver transplantation. Am J Transplant 2007; 7: 309-319.
21. Zhao X, Li Y, Ohe H, Nafady-Hego H, Uemoto S, Bishop GA et al. Intragraft Vdelta1 gammadelta T cells with a unique T-cell receptor are closely associated with pediatric semiallogeneic liver transplant tolerance. Transplantation 2013; 95: 192-202.
22. Hao J, Dong S, Xia S, He W, Jia H, Zhang S et al. Regulatory role of Vgamma1 gammadelta T cells in tumor immunity through IL-4 production. J Immunol 2011; 187: 4979-4986.
23. Wen L, Peakman M, Mieli-Vergani G, Vergani D. Elevation of activated gamma delta T cell receptor bearing T lymphocytes in patients with autoimmune chronic liver disease. Clin Exp Immunol 1992; 89: 78-82.
24. Rajan AJ, Asensio VC, Campbell IL, Brosnan CF. Experimental autoimmune encephalomyelitis on the SJL mouse: effect of gamma delta T cell depletion on chemokine and chemokine receptor expression in the central nervous system. J Immunol 2000; 164: 2120-2130.
25. + T cells regulate major histocompatibility complex class II(IA and IE)-dependent susceptibility to coxsackievirus B3-induced autoimmune myocarditis. J Virol 1999; 73: 5630-5636.
26. Agrati C, Castilletti C, de Santis R, Cimini E, Bordi L, Malkovsky M et al. Interferon-gamma-mediated antiviral immunity against orthopoxvirus infection is provided by gamma delta T cells. J Infect Dis 2006; 193: 1606-1607; author reply 1607-1608.
27. Petermann F, Rothhammer V, Claussen MC, Haas JD, Blanco LR, Heink S et al. gammadelta T cells enhance autoimmunity by restraining regulatory T cell responses via an interleukin-23-dependent mechanism. Immunity 2010; 33: 351-363.
28. Veldhoen M, Uyttenhove C, van Snick J, Helmby H, Westendorf A, Buer J et al. Transforming growth factor-beta 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat Immunol 2008; 9: 1341-1346.
29. - effector T cells. Nat Immunol 2008; 9: 1347-1355.
30. Onishi T, Ohishi Y, Imagawa K, Ohmoto Y, Murata K. An assessment of the immunological environment based on intratumoral cytokine production in renal cell carcinoma. BJU Int 1999; 83: 488-492.
31. Kawakami M, Kawakami K, Stepensky VA, Maki RA, Robin H, Muller W et al. Interleukin 4 receptor on human lung cancer: a molecular target for cytotoxin therapy. Clin Cancer Res 2002; 8: 3503-3511.
32. Kioi M, Takahashi S, Kawakami M, Kawakami K, Kreitman RJ, Puri RK. Expression and targeting of interleukin-4 receptor for primary and advanced ovarian cancer therapy. Cancer Res 2005; 65: 8388-8396.
33. Leland P, Taguchi J, Husain SR, Kreitman RJ, Pastan I, Puri RK. Human breast carcinoma cells express type II IL-4 receptors and are sensitive to antitumor activity of a chimeric IL-4-Pseudomonas exotoxin fusion protein in vitro and in vivo. Mol Med 2000; 6: 165-178.
34. Kawakami K, Kawakami M, Husain SR, Puri RK. Targeting interleukin-4 receptors for effective pancreatic cancer therapy. Cancer Res 2002; 62: 3575-3580.
35. Yi Y, He HW, Wang JX, Cai XY, Li YW, Zhou J et al. The functional impairment of HCC-infiltrating gammadelta T cells, partially mediated by regulatory T cells in a TGFbeta- and IL-10-dependent manner. J Hepatol 2013; 58: 977-983.
36. Seo N, Tokura Y, Takigawa M, Egawa K. Depletion of IL-10- and TGFbeta-producing regulatory gamma delta T cells by administering a daunomycin-conjugated specific monoclonal antibody in early tumor lesions augments the activity of CTLs and NK cells. J Immunol 1999; 163: 242-249.
37. Ye J, Ma C, Hsueh EC, Eickhoff CS, Zhang Y, Varvares MA et al. Tumorderived gammadelta regulatory T cells suppress innate and adaptive immunity through the induction of immunosenescence. J Immunol 2013; 190: 2403-2414.
38. Catellani S, Poggi A, Bruzzone A, Dadati P, Ravetti JL, Gobbi M et al. Expansion of Vdelta1 T lymphocytes producing IL-4 in low-grade non-Hodgkin lymphomas expressing UL-16-binding proteins. Blood 2007; 109: 2078-2085.
39. Kang N, Zhou J, Zhang T, Wang L, Lu F, Cui Y et al. Adoptive immunotherapy of lung cancer with immobilized anti-TCRgammadelta antibody-expanded human gammadelta T-cells in peripheral blood. Cancer Biol Ther 2009; 8: 1540-1549.
40. Li X, Kang N, Zhang X, Dong X, Wei W, Cui L et al. Generation of human regulatory gammadelta T cells by TCRgammadelta stimulation in the presence of TGF-beta and their involvement in the pathogenesis of systemic lupus erythematosus. J Immunol 2011; 186: 6693-6700.
41. Kabelitz D, Wesch D, Pitters E, Zoller M. Characterization of tumor reactivity of human V gamma 9V delta 2 gamma delta T cells in vitro and in SCID mice in vivo. J Immunol 2004; 173: 6767-6776.
42. Kong Y, Cao W, Xi X, Ma C, Cui L, He W. The NKG2Dlig and ULBP4 binds to TCRgamma9/delta2 and induces cytotoxicity to tumor cells through both TCRgammadelta and NKG2D. Blood 2009; 114: 310-317.
43. Dai Y, Chen H, Mo C, Cui L, He W. Ectopically-expressed human tumor biomarker MutS homologue 2 is a novel endogenous ligand that is recognized by human gammadelta T cells to induce innate anti-tumor/virus immunity. J Biol Chem 2012; 287: 16812-16819.
44. Lanca T, Correia DV, Moita CF, Raquel H, Neves-Costa A, Ferreira C et al. The MHC class Ib protein ULBP1 is a nonredundant determinant of leukemia/lymphoma susceptibility to gammadelta T-cell cytotoxicity. Blood 2010; 115: 2407-2411.
45. Rincon-Orozco B, Kunzmann V, Wrobel P, Kabelitz D, Steinle A, Herrmann T. Activation of V gamma 9V delta 2 T cells by NKG2D. J Immunol 2005; 175: 2144-2151.
46. Girardi M, Oppenheim DE, Steele CR, Lewis JM, Glusac E, Filler R et al. Regulation of cutaneous malignancy by gammadelta T cells. Science 2001; 294: 605-609.
47. Das H, Groh V, Kuijl C, Sugita M, Morita CT, Spies T et al. MICA engagement by human Vgamma2Vdelta2 T cells enhances their antigen-dependent effector function. Immunity 2001; 15: 83-93.
48. Lu J, Aggarwal R, Kanji S, Das M, Joseph M, Pompili V et al. Human ovarian tumor cells escape gammadelta T cell recognition partly by down regulating surface expression of MICA and limiting cell cycle related molecules. PLoS One 2011; 6: e23348.
49. + T cells. Blood 2008; 111: 1378-1386.
50. Brady J, Carotta S, Thong RP, Chan CJ, Hayakawa Y, Smyth MJ et al. The interactions of multiple cytokines control NK cell maturation. J Immunol 2010; 185: 6679-6688.
51. Ventre E, Brinza L, Schicklin S, Mafille J, Coupet CA, Marcais A et al. Negative regulation of NKG2D expression by IL-4 in memory CD8 T cells. J Immunol 2012; 189: 3480-3489.
52. He W, Hao J, Dong S, Gao Y, Tao J, Chi H et al. Naturally activated V gamma 4 gammadelta T cells play a protective role in tumor immunity through expression of eomesodermin. J Immunol 2010; 185: 126-133.
53. Dokouhaki P, Han M, Joe B, Li M, Johnston MR, Tsao MS et al. Adoptive immunotherapy of cancer using ex vivo expanded human gammadelta T cells: a new approach. Cancer Lett 2010; 297: 126-136.
54. Siegers GM, Dhamko H, Wang XH, Mathieson AM, Kosaka Y, Felizardo TC et al. Human Vdelta1 gammadelta T cells expanded from peripheral blood exhibit specific cytotoxicity against B-cell chronic lymphocytic leukemia-derived cells. Cytotherapy 2011; 13: 753-764.
55. Siegers GM, Ribot EJ, Keating A, Foster PJ. Extensive expansion of primary human gamma delta T cells generates cytotoxic effector memory cells that can be labeled with Feraheme for cellular MRI. Cancer Immunol Immunother 2013; 62: 571-583.
56. + subset for gammadelta-T-cell-based immunotherapy. J Immunother 2008; 31: 896-905.
57. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140: 883-899.